Adding experimental arms to platform clinical trials: randomization procedures and interim analyses.
暂无分享,去创建一个
Lorenzo Trippa | Matteo Cellamare | Giovanni Parmigiani | Steffen Ventz | G. Parmigiani | L. Trippa | S. Ventz | M. Cellamare
[1] W F Rosenberger,et al. Bootstrap methods for adaptive designs. , 1999, Statistics in medicine.
[2] J Jack Lee,et al. Bayesian adaptive randomization designs for targeted agent development , 2008, Clinical trials.
[3] J. Wason,et al. Correcting for multiple-testing in multi-arm trials: is it necessary and is it done? , 2014, Trials.
[4] Robert K Hills,et al. Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. , 2011, Blood.
[5] R. Gray,et al. Multi-Arm Clinical Trials of New Agents: Some Design Considerations , 2008, Clinical Cancer Research.
[6] Wenle Zhao,et al. Flexible Analytical Methods for Adding a Treatment Arm Mid-Study to an Ongoing Clinical Trial , 2012, Journal of biopharmaceutical statistics.
[7] Lorenzo Trippa,et al. A Bayesian response-adaptive trial in tuberculosis: The endTB trial , 2017, Clinical trials.
[8] Nigel Stallard,et al. To add or not to add a new treatment arm to a multiarm study: A decision‐theoretic framework , 2019, Statistics in medicine.
[9] Lorenzo Trippa,et al. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? , 2018, Neuro-oncology.
[10] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[11] J. Wason,et al. A comparison of Bayesian adaptive randomization and multi‐stage designs for multi‐arm clinical trials , 2014, Statistics in medicine.
[12] Ying Yuan,et al. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. , 2016, Statistics in medicine.
[13] Lars Kjeldsen,et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Lieberman,et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.
[15] Lorenzo Trippa,et al. Bayesian response‐adaptive designs for basket trials , 2017, Biometrics.
[16] Jeffrey R. Eisele. The doubly adaptive biased coin design for sequential clinical trials , 1994 .
[17] S. Todd,et al. Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice , 2015, Trials.
[18] G. Parmigiani,et al. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Thall,et al. Practical Bayesian adaptive randomisation in clinical trials. , 2007, European journal of cancer.
[20] Feifang Hu,et al. Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials , 2003 .
[21] Bradley P. Carlin,et al. Bayesian Adaptive Methods for Clinical Trials , 2010 .
[22] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[23] Brian P Hobbs,et al. Controlled multi-arm platform design using predictive probability , 2018, Statistical methods in medical research.
[24] J. Connor,et al. The platform trial: an efficient strategy for evaluating multiple treatments. , 2015, JAMA.